Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Angiosarcoma
Research on angiosarcoma discussed by scientists at University of Strasbourg
January 6th, 2009
According to a study from Strasbourg, France, "Angiosarcoma represents 1 to 2% of soft tissue tumors. It originates from endothelial cells of small blood vessels and may affect a variety of organs, including the retroperitoneum, skeletal muscle, subcutis, liver, heart and breast." "The outcome of angiosarcoma is poor for those patients in whom aggressive surgery cannot be considered. Chemotherapy, generally consisting of the combination of anthracyclines and ifosfamide, has little, but consistent effect. We report three cases of angiosarcoma in which first-line chemotherapy with adriamycin 40 mg/m(2) day 1, ifosfamide 3 g/m(2) day 1-2, cisplatin 35 mg/m(2) day 1-2 and...
Source: Cancer Weekly (2009-01-06)
|
